Australian stem cell company Cynata Therapeutics released news today than interim analysis clearly demonstrates efficacy of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, in a preclinical model of Graft-versus-Host disease (GvHD). This disease often follows a bone marrow transplant procedure and occurs when the immune cells in the donor material (the graft) attack the recipient’s tissues (the host) as “foreign”. Bone marrow transplants are used in the treatment of certain cancers, including leukaemia. [Read more…]
Cord Blood Market Consolidation Continues as “FamilyCord” Acquires Southern Cord Inc.
On November 13, 2015, AlphaCord released news that it was acquiring LifeSource Cryobank. The acquisition was AlphaCord’s fifth acquisition of smaller cord blood banks. Today, California Cryobank Stem Cell Services LLC, better known as “FamilyCord”, announced it has acquired Southern Cord Inc., a cord blood bank operating within the southeastern U.S.
Together, these recent mergers continue the trend of consolidation within the global cord blood banking market. [Read more…]
Cynata Therapeutics Enters Agreement for Strategic Alliance with Regience K.K. in Japan
In recently released news, Cynata Therapeutics announced that it has entered into a strategic alliance with Regience K.K., who will have an exclusive 2-year option to license Cynata’s unique Cymerus™ technology in Japan and certain other Asian countries.
Cynata’s Cymerus™ technology produces clinical-grade mesenchymal stem cells (MSCs) derived from a one-time donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue. This approach allows MSCs to be produced in nearly limitless quantities, eliminates product variability, and allows for lower manufacturing costs.
Cynata is an exciting company to watch, as highlighted by Rodman and Renshaw. To learn more, read the full press release from Cynata Therapeutics, included below. [Read more…]
1st Allogeneic Cell Therapy Product Released in Japan by Mesoblast Licensee, JCR Pharmaceuticals
Mesoblast announced that it is launching the first allogeneic cell therapy to ever achieve full approval in Japan, a mesenchymal stem cell (MSC) product TEMCELL® HS Inj. The product will be used for the treatment of acute graft versus host disease (aGVHD), sold through Mesoblast’s Japanese licensee, JCR Pharmaceuticals.
To learn more, read the full press release from Mesoblast below. [Read more…]
Did You See This Week’s Top Stem Cell News?
We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!
Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »